CA2230385A1 - Analogues pour interactions specifiques oligosaccharide-neureguline et leurs utilisations - Google Patents

Analogues pour interactions specifiques oligosaccharide-neureguline et leurs utilisations Download PDF

Info

Publication number
CA2230385A1
CA2230385A1 CA002230385A CA2230385A CA2230385A1 CA 2230385 A1 CA2230385 A1 CA 2230385A1 CA 002230385 A CA002230385 A CA 002230385A CA 2230385 A CA2230385 A CA 2230385A CA 2230385 A1 CA2230385 A1 CA 2230385A1
Authority
CA
Canada
Prior art keywords
neuregulin
sequence
binding
protein
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002230385A
Other languages
English (en)
Inventor
James Rusche
Judith Sudhalter
Alan R. Jacobson
Nagesh K. Mahanthappa
Mark A. Marchionni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Repligen Corp
Cenes Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2230385A1 publication Critical patent/CA2230385A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Radiology & Medical Imaging (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

L'invention concerne des procédés de modulation de l'interaction entre des neurégulines et des séquences de glycosaminoglycanes spécifiques des neurégulines. L'invention identifie des composés capables d'imiter une interaction spécifique entre les séquences de neurégulines-glycosaminogycanes et constitue un procédé permettant leur sélection ainsi que leur utilisation en tant qu'agents thérapeutiques.
CA002230385A 1995-09-05 1996-09-04 Analogues pour interactions specifiques oligosaccharide-neureguline et leurs utilisations Abandoned CA2230385A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US317595P 1995-09-05 1995-09-05
US60/003,175 1995-09-05

Publications (1)

Publication Number Publication Date
CA2230385A1 true CA2230385A1 (fr) 1997-03-13

Family

ID=21704553

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002230385A Abandoned CA2230385A1 (fr) 1995-09-05 1996-09-04 Analogues pour interactions specifiques oligosaccharide-neureguline et leurs utilisations

Country Status (5)

Country Link
EP (1) EP0848613A1 (fr)
JP (1) JP2000510879A (fr)
AU (1) AU6965696A (fr)
CA (1) CA2230385A1 (fr)
WO (1) WO1997009051A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU744060B2 (en) * 1997-05-09 2002-02-14 Pharm-Eco Laboratories, Inc. Building blocks derived from 1,2-aminoalcohols
US6590106B2 (en) 1997-05-09 2003-07-08 Pharm-Eco Laboratories, Inc. Amino acid derivatives and methods of making the same
US6479669B2 (en) 1997-05-09 2002-11-12 Pharm-Eco Laboratories, Inc. Amino acid derivatives and methods of making the same
AU3368899A (en) * 1998-03-30 1999-10-18 Cambridge Neuroscience, Inc. Protein-carbohydrate binding antagonists
US6852696B2 (en) 1999-03-26 2005-02-08 The University Of Texas System Inhibitors of glycosaminoglycans
JP2004532203A (ja) * 2001-03-21 2004-10-21 ザ、ユニバーシティ、オブ、テキサス、システム グリコサミノグリカンの阻害剤
JP4314113B2 (ja) 2001-07-31 2009-08-12 ウェイン・ステイト・ユニバーシティ ヘパラン硫酸プロテオグリカンに対する標的化のための、ニューレグリンヘパリン結合ドメインとのハイブリッドタンパク質

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2584728B1 (fr) * 1985-07-12 1987-11-20 Choay Sa Procede de sulfatation de glycosaminoglycanes et de leurs fragments
US4859581A (en) * 1986-03-10 1989-08-22 Board Of Regents, The University Of Texas System Endoglycosidase assay

Also Published As

Publication number Publication date
AU6965696A (en) 1997-03-27
JP2000510879A (ja) 2000-08-22
EP0848613A1 (fr) 1998-06-24
WO1997009051A1 (fr) 1997-03-13

Similar Documents

Publication Publication Date Title
Curtis et al. Retrograde axonal transport of LIF is increased by peripheral nerve injury: correlation with increased LIF expression in distal nerve
Henrichsen et al. Bioaffinity NMR Spectroscopy: Identification of an E‐Selectin Antagonist in a Substance Mixture by Transfer NOE
US5342942A (en) Pyrazoloquinazolone derivatives as neurotrophic agents
CA2486106C (fr) Composes et procedes d'inhibition des fonctions induites par les selectines
EP1640381A2 (fr) Facteur de croissance néurotrophique
AU652624B2 (en) The (trk) tyrosine kinase receptor is the physiological receptor for nerve growth factor
KR20010085767A (ko) 결합 조직 성장 인자를 조정, 조절 및 억제함에 의하여신장 장애를 검출, 예방 및 치료하는 방법
CA2230385A1 (fr) Analogues pour interactions specifiques oligosaccharide-neureguline et leurs utilisations
US20040096396A1 (en) Compositions and methods for diagnosis and therapy of medical conditions involving angiogenesis
EP0688327B1 (fr) Analogues d'interactions specifiques oligosaccharide-proteine et leur utilisations
CA3056206A1 (fr) Glycopolymeres sequestrant des proteines de liaison aux glucides
EP4043435A1 (fr) Composé pour la détection de cellules sénéscentes et utilisation de celui-ci
US5332672A (en) Prevention of ES cell differentiation by ciliary neurotrophic factor
CA2272356C (fr) Polypeptides solubles
AU2005262332A1 (en) Small molecule inhibition of a PDZ-domain interaction
CA2376164C (fr) Composes a association intermoleculaire et agregats englobant ces composes
US6492417B1 (en) 11-deoxy-16-fluoro-PGF2α analogs as FP receptor antagonists
CA2411067A1 (fr) Oligopeptides
JP2001136974A (ja) 生理活性ピロールイミダゾール誘導体のスクリーニング方法
CA2633264A1 (fr) Nouveaux composes interagissant avec pea-15
US5955290A (en) Assay systems using the CNTF signal transduction pathway
US5811396A (en) TRK tyrosine kinase receptor is the physiological receptor for nerve growth factor
JP3457321B2 (ja) Ｃｎｔｆシグナル形質導入経路を用いたアッセイ系
CN119330934B (zh) 一种靶向Smurf1蛋白的降解剂、制备方法及用途
WO1993011253A1 (fr) Complexe recepteur/facteur neurotrophique ciliaire exempt de cellules

Legal Events

Date Code Title Description
FZDE Discontinued